Table 1.
The relationship between miR-17 expression and clinicopathological parameters
| Characteristics | miR-17 expression
|
P-value | |
|---|---|---|---|
| Low (n=48), n (%) |
High (n=44), n (%) |
||
| Age(years) | 1 | ||
| ≥50 | 21 (43.8) | 20 (45.4) | |
| <50 | 27 (56.2) | 24 (54.6) | |
| COX-2 | 1 | ||
| Positive | 23 (47.9) | 21 (47.7) | |
| Negative | 25 (52.1) | 23 (52.3) | |
| CD44 | 0.68 | ||
| Positive | 24 (50.0) | 24 (54.5) | |
| Negative | 24 (50.0) | 20 (45.5) | |
| EGFR | 0.8 | ||
| Positive | 15 (42.9) | 13 (38.2) | |
| Negative | 20 (57.1) | 21 (62.8) | |
| ER | 0.006 | ||
| Positive | 20 (41.7) | 31 (70.5) | |
| Negative | 28 (58.3) | 13 (29.5) | |
| PR | 0.83 | ||
| Positive | 24 (50.0) | 21 (47.7) | |
| Negative | 24 (50.0) | 23 (52.3) | |
| HER-2 | 0.0007 | ||
| Positive | 20 (41.7) | 34 (77.3) | |
| Negative | 28 (58.3) | 10 (22.7) | |
| PGP | 0.17 | ||
| Positive | 12 (44.5) | 19 (65.5) | |
| Negative | 15 (55.5) | 10 (34.5) | |
| Lymph node metastasis | 0.29 | ||
| Positive | 26 (54.1) | 29 (65.9) | |
| Negative | 22 (45.9) | 15 (34.1) | |
Abbreviations: COX-2, cyclooxygenase-2; EGFR, epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; PGP, P-glycoprotein.